{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=6",
    "query": {
      "intervention": "Torisel",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 647,
    "total_pages": 65,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Torisel&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T14:56:26.703Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00743509",
      "title": "A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide and Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2008-08",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2015-09-28",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743509"
    },
    {
      "nct_id": "NCT00693433",
      "title": "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Multiple Myeloma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2008-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-12-04",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Las Angeles, California",
      "locations": [
        {
          "city": "Las Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00693433"
    },
    {
      "nct_id": "NCT00483262",
      "title": "Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CCI-779",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2007-05",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2013-11-11",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00483262"
    },
    {
      "nct_id": "NCT05840510",
      "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "NSCLC",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Malignant Neoplastic Disease"
      ],
      "interventions": [
        {
          "name": "Adagrasib",
          "type": "DRUG"
        },
        {
          "name": "nab-Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-08-07",
      "completion_date": "2024-12-27",
      "has_results": false,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Nashville, Tennessee • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05840510"
    },
    {
      "nct_id": "NCT00891696",
      "title": "Nutritional and Contractile Regulation of Muscle Growth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcopenia"
      ],
      "interventions": [
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "Amino acid supplementation",
          "type": "OTHER"
        },
        {
          "name": "Low-intensity resistance exercise",
          "type": "OTHER"
        },
        {
          "name": "Sodium nitroprusside",
          "type": "DRUG"
        },
        {
          "name": "Blood flow restriction cuff",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 144,
      "start_date": "2009-04",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2017-05-04",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00891696"
    },
    {
      "nct_id": "NCT00378703",
      "title": "Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2007-09-14",
      "completion_date": "2017-03-21",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 558,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 356 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00378703"
    },
    {
      "nct_id": "NCT00655655",
      "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastrinoma",
        "Glucagonoma",
        "Insulinoma",
        "Metastatic Gastrointestinal Carcinoid Tumor",
        "Metastatic Pheochromocytoma",
        "Pancreatic Polypeptide Tumor",
        "Recurrent Gastrointestinal Carcinoid Tumor",
        "Recurrent Islet Cell Carcinoma",
        "Recurrent Melanoma",
        "Recurrent Neuroendocrine Carcinoma of the Skin",
        "Recurrent Non-small Cell Lung Cancer",
        "Recurrent Pheochromocytoma",
        "Recurrent Renal Cell Cancer",
        "Somatostatinoma",
        "Stage III Neuroendocrine Carcinoma of the Skin",
        "Stage IV Melanoma",
        "Stage IV Non-small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Thyroid Gland Medullary Carcinoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "vatalanib",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "dynamic contrast-enhanced magnetic resonance imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "ultrasound imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2004-12",
      "completion_date": "2018-01-11",
      "has_results": false,
      "last_update_posted_date": "2024-08-21",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00655655"
    },
    {
      "nct_id": "NCT04562532",
      "title": "Firehawk Rapamycin Target Eluting Coronary Stent North American Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Microport Firehawk stent",
          "type": "DEVICE"
        },
        {
          "name": "2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Shanghai MicroPort Medical (Group) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1720,
      "start_date": "2021-02-17",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04562532"
    },
    {
      "nct_id": "NCT00349206",
      "title": "Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Recurrent Melanoma",
        "Stage III Melanoma",
        "Stage IV Melanoma"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2006-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00349206"
    },
    {
      "nct_id": "NCT00784914",
      "title": "A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "cytokine levels",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2008-06",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2018-04-17",
      "last_synced_at": "2026-10-27T14:56:26.703Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00784914"
    }
  ]
}